JP2011500003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500003A5 JP2011500003A5 JP2010527594A JP2010527594A JP2011500003A5 JP 2011500003 A5 JP2011500003 A5 JP 2011500003A5 JP 2010527594 A JP2010527594 A JP 2010527594A JP 2010527594 A JP2010527594 A JP 2010527594A JP 2011500003 A5 JP2011500003 A5 JP 2011500003A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- compound
- compound according
- moiety
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002652 ribonucleotide group Chemical group 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 3
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 3
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000035657 Abasia Diseases 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 102100032616 Caspase-2 Human genes 0.000 claims 2
- 101000867612 Homo sapiens Caspase-2 Proteins 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- -1 ATF3 Proteins 0.000 claims 1
- 102100029592 Activator of apoptosis harakiri Human genes 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 102100021986 Apoptosis-stimulating of p53 protein 2 Human genes 0.000 claims 1
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 claims 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 1
- 101150060120 C1qbp gene Proteins 0.000 claims 1
- 102100031168 CCN family member 2 Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102100037078 Complement component 1 Q subcomponent-binding protein, mitochondrial Human genes 0.000 claims 1
- 102100025620 Cytochrome b-245 light chain Human genes 0.000 claims 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 claims 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 108010083068 Dual Oxidases Proteins 0.000 claims 1
- 102100021218 Dual oxidase 1 Human genes 0.000 claims 1
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000987827 Homo sapiens Activator of apoptosis harakiri Proteins 0.000 claims 1
- 101000752711 Homo sapiens Apoptosis-stimulating of p53 protein 2 Proteins 0.000 claims 1
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 claims 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 1
- 101000856723 Homo sapiens Cytochrome b-245 light chain Proteins 0.000 claims 1
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 claims 1
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 claims 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 claims 1
- 101001108225 Homo sapiens NADPH oxidase 3 Proteins 0.000 claims 1
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 claims 1
- 101000589450 Homo sapiens Poly(ADP-ribose) glycohydrolase Proteins 0.000 claims 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 1
- 101001129796 Homo sapiens p53-induced death domain-containing protein 1 Proteins 0.000 claims 1
- 108700012928 MAPK14 Proteins 0.000 claims 1
- 101150003941 Mapk14 gene Proteins 0.000 claims 1
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 claims 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 claims 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 claims 1
- 102100021874 NADPH oxidase 3 Human genes 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims 1
- 102100032347 Poly(ADP-ribose) glycohydrolase Human genes 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 101150111584 RHOA gene Proteins 0.000 claims 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 108091081021 Sense strand Proteins 0.000 claims 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims 1
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 claims 1
- 102000003615 TRPM2 Human genes 0.000 claims 1
- 101150095096 TRPM2 gene Proteins 0.000 claims 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 102100022387 Transforming protein RhoA Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 102100031691 p53-induced death domain-containing protein 1 Human genes 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99757607P | 2007-10-03 | 2007-10-03 | |
| US60/997,576 | 2007-10-03 | ||
| US66407P | 2007-10-25 | 2007-10-25 | |
| US61/000,664 | 2007-10-25 | ||
| US353507P | 2007-11-15 | 2007-11-15 | |
| US61/003,535 | 2007-11-15 | ||
| US1004008P | 2008-01-04 | 2008-01-04 | |
| US61/010,040 | 2008-01-04 | ||
| US12851908P | 2008-05-22 | 2008-05-22 | |
| US61/128,519 | 2008-05-22 | ||
| US13463808P | 2008-07-10 | 2008-07-10 | |
| US61/134,638 | 2008-07-10 | ||
| US18903508P | 2008-08-15 | 2008-08-15 | |
| US61/189,035 | 2008-08-15 | ||
| PCT/IL2008/001197 WO2009044392A2 (en) | 2007-10-03 | 2008-09-04 | Novel sirna structures |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014125717A Division JP2014210789A (ja) | 2007-10-03 | 2014-06-18 | 新規ｓｉＲＮＡ構造 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500003A JP2011500003A (ja) | 2011-01-06 |
| JP2011500003A5 true JP2011500003A5 (enExample) | 2011-10-27 |
| JP5646997B2 JP5646997B2 (ja) | 2014-12-24 |
Family
ID=40526792
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527594A Expired - Fee Related JP5646997B2 (ja) | 2007-10-03 | 2008-09-04 | 新規ｓｉＲＮＡ構造 |
| JP2014125717A Pending JP2014210789A (ja) | 2007-10-03 | 2014-06-18 | 新規ｓｉＲＮＡ構造 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014125717A Pending JP2014210789A (ja) | 2007-10-03 | 2014-06-18 | 新規ｓｉＲＮＡ構造 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8614309B2 (enExample) |
| EP (1) | EP2231168A4 (enExample) |
| JP (2) | JP5646997B2 (enExample) |
| KR (1) | KR20100085951A (enExample) |
| CN (2) | CN101815521B (enExample) |
| AU (1) | AU2008306455C1 (enExample) |
| BR (1) | BRPI0817605A2 (enExample) |
| CA (1) | CA2701845A1 (enExample) |
| RU (1) | RU2487716C2 (enExample) |
| WO (1) | WO2009044392A2 (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20100292301A1 (en) * | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| US20110105584A1 (en) * | 2007-12-12 | 2011-05-05 | Elena Feinstein | Rtp80il sirna compounds and methods of use thereof |
| WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
| EP3643782A1 (en) | 2008-02-11 | 2020-04-29 | Phio Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
| WO2009116037A2 (en) * | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801 |
| WO2009144704A2 (en) * | 2008-04-15 | 2009-12-03 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS FOR INHIBITING NRF2 |
| US8431692B2 (en) * | 2008-06-06 | 2013-04-30 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| TWI455944B (zh) | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| EP2331141B1 (en) | 2008-08-25 | 2016-01-06 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| CN108165548B (zh) | 2008-09-22 | 2022-10-14 | 菲奥医药公司 | 减小大小的自递送RNAi化合物 |
| NZ591391A (en) | 2008-10-22 | 2012-10-26 | Quark Pharmaceuticals Inc | Non-invasive methods for treating eye disorders using a topical oligonucleotide composition |
| WO2010046889A1 (en) * | 2008-10-23 | 2010-04-29 | Quark Pharmaceuticals, Inc. | Methods for delivery of sirna to bone marrow cells and uses thereof |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| US20110288155A1 (en) | 2008-12-18 | 2011-11-24 | Elena Feinstein | Sirna compounds and methods of use thereof |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| CN104861066B (zh) | 2009-03-23 | 2018-05-08 | 夸克制药公司 | 治疗癌症和纤维化疾病的化合物组合物和方法 |
| US8637482B2 (en) * | 2009-06-08 | 2014-01-28 | Quark Pharmaceuticals, Inc. | Methods for treating chronic kidney disease |
| EP2264169A1 (en) * | 2009-06-15 | 2010-12-22 | Qiagen GmbH | Modified siNA |
| GB0910723D0 (en) | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| CN102666856B (zh) | 2009-11-08 | 2016-04-06 | 夸克制药公司 | 定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途 |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| US8778904B2 (en) | 2009-12-09 | 2014-07-15 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the CNS |
| ES2562499T3 (es) * | 2009-12-09 | 2016-03-04 | Nitto Denko Corporation | Modulación de la expresión de HSP47 |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| KR102453078B1 (ko) | 2010-03-24 | 2022-10-11 | 피오 파마슈티칼스 코프. | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| RU2012153703A (ru) * | 2010-06-24 | 2014-07-27 | Кварк Фармасьютикалс, Инк. | Соединения двухцепочечных рнк к rhoa и их применение |
| JP6106085B2 (ja) * | 2010-08-24 | 2017-03-29 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤 |
| GB201015974D0 (en) * | 2010-09-23 | 2010-11-03 | Univ Warwick | Sirna |
| CA2818662C (en) | 2010-10-22 | 2021-07-06 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid molecule inducing rna interference, and uses thereof |
| EP2649181B1 (en) * | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| MX365647B (es) | 2011-02-02 | 2019-06-10 | Excaliard Pharmaceuticals Inc | El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas. |
| AU2012223366B2 (en) | 2011-03-03 | 2017-02-23 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| AU2012332517B9 (en) | 2011-11-03 | 2017-08-10 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
| US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| JP2015509085A (ja) | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． | 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 |
| CA2858627C (en) | 2012-01-04 | 2020-12-01 | Quark Pharmaceuticals, Inc. | Double-stranded rna compounds to casp2 and uses thereof |
| CN102743763B (zh) * | 2012-04-11 | 2013-11-06 | 中山大学中山眼科中心 | 一种治疗青光眼的药物 |
| CN102703508A (zh) * | 2012-05-18 | 2012-10-03 | 边红 | 靶向GSK3β基因RNA干扰重组慢病毒载体及其构建、筛选方法 |
| EP3514236A1 (en) * | 2012-05-22 | 2019-07-24 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
| CA2880290C (en) | 2012-09-12 | 2020-10-27 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof |
| ES2704855T3 (es) | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
| US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
| CN102911940B (zh) * | 2012-10-11 | 2014-02-05 | 江苏省疾病预防控制中心 | 特异性抑制nk细胞受体kir3dl1的小核酸干扰分子及其应用 |
| EP2958998B1 (en) * | 2013-02-22 | 2017-12-27 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage |
| EP3027222A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
| US20160208247A1 (en) | 2013-07-31 | 2016-07-21 | Qbi Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
| US10144928B2 (en) | 2013-08-23 | 2018-12-04 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
| EP2865757A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene. |
| EP2865758A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
| EP2865756A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene. |
| CN113151180A (zh) | 2013-12-02 | 2021-07-23 | 菲奥医药公司 | 癌症的免疫治疗 |
| KR101696704B1 (ko) * | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| SI3444349T1 (sl) * | 2014-05-29 | 2021-07-30 | Quark Pharmaceuticals, Inc. | Postopki in sestavki za preprečevanje ishemične reperfuzijske poškodbe v organih |
| CA2951721C (en) | 2014-06-12 | 2023-09-26 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
| KR102689262B1 (ko) | 2014-09-05 | 2024-07-30 | 피오 파마슈티칼스 코프. | Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| EP3862005A1 (en) | 2015-07-06 | 2021-08-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
| MA44908A (fr) | 2015-09-08 | 2018-07-18 | Sylentis Sau | Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp |
| US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
| EP3377630A4 (en) | 2015-11-16 | 2020-01-01 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 |
| CN108779463B (zh) | 2016-02-02 | 2022-05-24 | 奥利克斯医药有限公司 | 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘 |
| WO2017134526A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb |
| EP3420087B1 (en) * | 2016-02-23 | 2021-09-01 | The Regents of The University of Colorado, A Body Corporate | Peptide-based methods for treating neurological injury |
| WO2017178883A2 (en) | 2016-04-11 | 2017-10-19 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| KR20190058477A (ko) | 2016-08-17 | 2019-05-29 | 솔스티스 바이올로직스, 리미티드 | 폴리뉴클레오티드 구축물 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| KR20190100225A (ko) * | 2016-12-28 | 2019-08-28 | 다이이찌 산쿄 가부시키가이샤 | 알포트 증후군 치료약 |
| US11591600B2 (en) | 2017-02-10 | 2023-02-28 | OliX Pharmaceuticals. Inc. | Long double-stranded RNA for RNA interference |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| EP3790557A4 (en) * | 2018-05-07 | 2022-03-02 | Alnylam Pharmaceuticals Inc. | COMPOSITIONS AND METHODS FOR ENHANCING STRAND DISTORTION |
| MX2022002397A (es) * | 2019-08-27 | 2022-08-25 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de c3 en una celula. |
| KR102757180B1 (ko) * | 2019-11-22 | 2025-01-21 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| US20230151369A1 (en) * | 2020-04-17 | 2023-05-18 | The University Of British Columbia | Compositions and methods for inhibiting tdp-43 and fus aggregation |
| WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
| EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
| MX2023014008A (es) * | 2021-05-27 | 2023-12-11 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para silenciar la expresion de anhidrasa carbonica 2. |
| CA3231695A1 (en) * | 2021-09-08 | 2023-03-16 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| AU2022418939A1 (en) * | 2021-12-22 | 2024-03-21 | Na Vaccine Institute | Composition for preventing or treating ischemia-reperfusion injury and use thereof |
| EP4560019A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
| EP4560020A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| JP3119871B2 (ja) | 1990-07-26 | 2000-12-25 | 株式会社医薬分子設計研究所 | オリゴデオキシリボヌクレオチド類 |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| US6235886B1 (en) * | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| JPH08511690A (ja) | 1993-06-24 | 1996-12-10 | ザ・ジェネラル・ホスピタル・コーポレーション | プログラムされた細胞死遺伝子及びタンパク質 |
| WO1995006731A2 (en) * | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| US5858678A (en) | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
| US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| EP0799892A3 (en) * | 1996-04-05 | 1998-08-12 | Takeda Chemical Industries, Ltd. | Calpain, its production and use |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US20050032067A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
| US5929042A (en) * | 1997-03-03 | 1999-07-27 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
| US7223856B2 (en) | 1997-03-03 | 2007-05-29 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6251666B1 (en) * | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6458590B1 (en) | 1997-08-07 | 2002-10-01 | The United States Of America, As Represented By The Department Of Health And Human Services | Methods and compositions for treatment of restenosis |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| WO1999009046A1 (en) | 1997-08-21 | 1999-02-25 | Quark Biotech, Inc. | Hypoxia-regulated genes |
| KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
| US20030125277A1 (en) | 2001-11-08 | 2003-07-03 | Isis Pharmaceuticals Inc. | Antisense modulation of activating transcription factor 3 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| PT1146908E (pt) | 1999-01-27 | 2005-10-31 | David Dr Becker | Formulacoes que contem nucleotidos de anti-sentido para conexinas |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| NZ513402A (en) * | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
| AU3369900A (en) | 1999-02-19 | 2000-09-04 | General Hospital Corporation, The | Gene silencing |
| US20040171566A1 (en) | 1999-04-06 | 2004-09-02 | Monia Brett P. | Antisense modulation of p38 mitogen activated protein kinase expression |
| US6140124A (en) | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
| WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| WO2001018037A2 (en) | 1999-09-07 | 2001-03-15 | University Health Network | A p53-induced protein with a death domain that can promote apoptosis |
| HK1047109A1 (zh) * | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9925459D0 (en) * | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
| CA2389765A1 (en) | 1999-11-02 | 2001-05-10 | Chiron Corporation | Cpg receptor (cpg-r) and methods relating thereto |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| US6323029B1 (en) | 2000-01-19 | 2001-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of glycogen synthase kinase 3 beta expression |
| US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20050020525A1 (en) * | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| EP1309726B2 (en) * | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| WO2002024720A1 (en) | 2000-09-20 | 2002-03-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 2 expression |
| FR2815541B1 (fr) | 2000-10-24 | 2008-02-29 | Lipha | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique |
| RU2322500C2 (ru) * | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US20070032441A1 (en) * | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| CA2452458A1 (en) * | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| GB0116955D0 (en) | 2001-07-11 | 2001-09-05 | Syngenta Ltd | Weed control process |
| ES2346640T4 (es) * | 2001-10-26 | 2011-04-26 | Noxxon Pharma Ag | Ácido l-nucleico modificado. |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| CA2467936C (en) * | 2001-11-21 | 2013-11-05 | Mitsubishi Chemical Corporation | Method of inhibiting gene expression |
| WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| CA2482904A1 (en) | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| AU2003256636A1 (en) | 2002-07-22 | 2004-02-09 | University Of Miami | Preventing ischemia-induced cell damage |
| AU2003268023A1 (en) | 2002-07-23 | 2004-02-09 | Incyte Corporation | Protein modification and maintenance molecules |
| ES2280826T5 (es) * | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| US20040142865A1 (en) | 2002-10-02 | 2004-07-22 | Weber Georg F. | Osteopontin-based cancer therapies |
| JP2006517916A (ja) | 2002-10-30 | 2006-08-03 | ザ シービーアール インスティテュート フォー バイオメディカル リサーチ インコーポレーティッド | Ｒｎａ干渉物質を用いてアポトーシス関連疾患を治療および予防する方法 |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| AU2002952550A0 (en) | 2002-11-08 | 2002-11-21 | The University Of Queensland | Modulating TNFalpha Secretion |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| US20050233342A1 (en) | 2003-03-07 | 2005-10-20 | Muthiah Manoharan | Methods of preventing off-target gene silencing |
| ES2576677T3 (es) | 2003-03-21 | 2016-07-08 | Roche Innovation Center Copenhagen A/S | Análogos de ARN interfirientes cortos |
| JP4991297B2 (ja) | 2003-05-22 | 2012-08-01 | キエジ ファルマチェウティチ エッセ・ピ・ア | 細胞死を予防および治療するための手段およびそれらの生物学的適用 |
| AU2004248136B2 (en) * | 2003-06-02 | 2011-09-15 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
| ATE485394T1 (de) * | 2003-06-02 | 2010-11-15 | Univ Massachusetts | Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai |
| WO2005044976A2 (en) * | 2003-06-20 | 2005-05-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| WO2005041857A2 (en) | 2003-10-07 | 2005-05-12 | Quark Biotech, Inc. | Bone morphogenetic protein (bmp) 2a and uses thereof |
| WO2005103297A1 (en) | 2004-03-31 | 2005-11-03 | Georgetown University | METHODS AND COMPOSITIONS RELATED TO MODULATION OF p22phox |
| KR101147147B1 (ko) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| EP1740614A2 (en) * | 2004-04-30 | 2007-01-10 | Theraptosis S.A. | Caspase-2 inhibitors and their biological applications |
| WO2005110464A2 (en) * | 2004-05-14 | 2005-11-24 | Oregon Health & Science University | Irx5 inhibition as treatment for hyperproliferative disorders |
| CA2568735A1 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
| EP2990410A1 (en) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| KR100939274B1 (ko) * | 2004-08-16 | 2010-01-29 | 쿠아크 파마수티칼스 인코퍼레이티드 | 알티피801 억제제의 치료적 용도 |
| JP4991547B2 (ja) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| TW200639253A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
| US7772200B2 (en) * | 2005-07-21 | 2010-08-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeted to the Rho-A gene |
| CA2619876A1 (en) * | 2005-08-17 | 2007-02-22 | Sirna Therapeutics, Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| NL2000439C2 (nl) * | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
| US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
| US8362229B2 (en) * | 2006-02-08 | 2013-01-29 | Quark Pharmaceuticals, Inc. | Tandem siRNAS |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
-
2008
- 2008-09-04 CA CA2701845A patent/CA2701845A1/en not_active Abandoned
- 2008-09-04 WO PCT/IL2008/001197 patent/WO2009044392A2/en not_active Ceased
- 2008-09-04 JP JP2010527594A patent/JP5646997B2/ja not_active Expired - Fee Related
- 2008-09-04 BR BRPI0817605A patent/BRPI0817605A2/pt not_active IP Right Cessation
- 2008-09-04 RU RU2010113514/10A patent/RU2487716C2/ru not_active IP Right Cessation
- 2008-09-04 CN CN200880110087.0A patent/CN101815521B/zh not_active Expired - Fee Related
- 2008-09-04 CN CN201210369167.6A patent/CN103898110A/zh active Pending
- 2008-09-04 KR KR1020107009512A patent/KR20100085951A/ko not_active Ceased
- 2008-09-04 EP EP08808012A patent/EP2231168A4/en not_active Withdrawn
- 2008-09-04 US US12/733,998 patent/US8614309B2/en active Active
- 2008-09-04 AU AU2008306455A patent/AU2008306455C1/en not_active Ceased
-
2012
- 2012-08-27 US US13/595,519 patent/US20130123334A1/en not_active Abandoned
-
2014
- 2014-06-18 JP JP2014125717A patent/JP2014210789A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500003A5 (enExample) | ||
| RU2487716C2 (ru) | Новые структуры малых интерферирующих рнк (sirna) | |
| JP2013511990A5 (enExample) | ||
| JP6426268B2 (ja) | 新規の二重らせんオリゴｒｎａおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物 | |
| JP2020058368A5 (enExample) | ||
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2020500929A5 (enExample) | ||
| JP2013535212A5 (enExample) | ||
| JP2010505432A5 (enExample) | ||
| JP6771387B2 (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP7636333B2 (ja) | 肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法 | |
| CN115819484A (zh) | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 | |
| KR20240116539A (ko) | LPA를 표적으로 하는 siRNA 및 접합체 | |
| CN118541482A (zh) | 一种dsRNA、其制备方法及应用 | |
| JP2013537404A5 (enExample) | ||
| WO2003004511A3 (en) | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | |
| WO2008004610A1 (en) | Method of treating genetic disease caused by nonsense mutation | |
| JP2020521491A5 (enExample) | ||
| CN118525092A (zh) | 一种dsRNA、其应用及制备方法 | |
| KR20150064065A (ko) | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna 를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2025528393A (ja) | Ｒｎａペイロードの転写を増やすための操作された構築物 | |
| CN120202298A (zh) | 一种抑制sod1基因表达的dsRNA分子及其应用 | |
| JPWO2022251394A5 (enExample) | ||
| TW202340470A (zh) | 一種ｄｓｒｎａ、其應用及製備方法 |